Context Therapeutics Inc. · NASDAQ:CNTX
Context Therapeutics — Investor Presentation (November 2026)
37 slides from Context Therapeutics's investor presentation, Nov 10, 2026
Slide 1: Corporate Presentation: Advancing T Cell Engagers for Solid Tumors
November 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the Company’s strategy, future operations, pros
Slide 3: Executive Summary: Pipeline Overview
Executive Summary Pipeline Overview 3 PROGRAM TARGET LEAD INDICATION(S) PRECLINICAL PHASE 1 PHASE 2 ANTICIPATED MILESTONES CTIM-76 Claudin 6 Platinum-resistant ovarian cancer (PROC) Q1 2027: Initiate Phase 1b Q2 2027: Phase 1a initial Q3W dosing data CT-202 Nectin-4 Urothelial, colorectal, TNBC 2H 2
Slide 4: T Cell Engaging (TCE) Bispecific Antibodies: Mechanism of Action
T Cell Engaging (TCE) Bispecific Antibodies Executive Summary Context Therapeutics Inc. - November 20264 Mechanism of Action T cell engagers are specialized medicines that help the body's own immune cells find and attack cancer. Each one works like a bridge: one end grabs onto a marker on the cancer
Slide 5: Context is Positioned to Develop the Next Generation of T Cell Engagers
Context is Positioned to Develop the Next Generation of T Cell Engagers Potential to expand into early treatment lines through rational drug combinations Executive Summary Context Therapeutics Inc. - November 20265 Future Development Combination Approaches Near Term Development Optimized Novel Monot
Slide 6: CTIM-76 CLDN6 x CD3 bispecific antibody
CTIM-76 CLDN6 x CD3 bispecific antibody Context Therapeut ics Inc . - November 20266
Slide 7: Initial Focus on Platinum-resistant Ovarian Cancer (PROC)
Our Initial Focus is on Platinum-resistant Ovarian Cancer (PROC) ~75% of PROC patients are CLDN6+ No approved treatment option specifically for this biomarker selected PROC population ~42,000 CLDN6+ PROC patients across United States, EU7, and Japan CLDN6 has significant target overlap with promisin
Slide 8: CLDN6 is an Attractive Target for Immunotherapy
CLDN6 is an Attractive Target for Immunotherapy • CLDN6 is an oncofetal protein: expressed during embryonic development, silenced or very low in normal adult tissue. • Expression increases with cancer disease stage • Tetraspan membrane protein with low internalization, favoring a TCE over an ADC, wh
Slide 9: CTIM-76: Claudin x CD3 T cell Engaging Bispecific Antibody
CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Designed to restrict T cell activation to CLDN6-expressing target cells • CLDN6-selective fragment antigen-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functionally monovalent to a
Slide 10: CTIM-76 is a Highly Selective and Potent CLDN6 x CD3 Bispecific
CTIM-76 Program CTIM-76 is a Highly Selective and Potent CLDN6 x CD3 Bispecific Antibody CTIM-76 CLDN6 EC50 of 3.41 nM (binding) CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 CLDN3/4/6/9 were transiently transfected in HEK-293F cells >10,000x Potency assay provides a physiologically-relevant
Slide 11: CTIM-76 Phase 1 Study Design
CTIM-76 Program CTIM-76 Phase 1 Study Design Context Therapeutics Inc. - November 202611 An open-label, multi-center, dose escalation / expansion, safety, and PK study Screening Phase 1a Dose Escalation (QW Dosing) Key Inclusion Criteria • CLDN6-positive by IHC (≥10% 1+ staining) • Age ≥18 years • M
Slide 12: Phase 1a Clinical Data Observed with CTIM-76
Phase 1a Clinical Data Observed with CTIM-76 CTIM-76 Program Context Therapeutics Inc. - November 202612 CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. *RECIST-evaluable PROC population (n=9 patients at target doses) is defined as having measurable disease documented at baseline according t
Slide 13: CTIM-76 Patient Demographics
CTIM-76 Patient Demographics CTIM-76 evaluated in heavily pretreated patients with high tumor burden CTIM-76 Program Context Therapeutics Inc. - November 202613 CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. All treated patients (≥1 dose). Age and ECOG at screen
Slide 14: CTIM-76 Safety Summary
CTIM-76 Safety Summary CTIM-76 Program CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. Each patient is counted once per row. TEAE = treatment-emergent adverse event, meaning a side effect or health problem that started on or after the first day of treatment; rela
Slide 15: Grade ≥3 Adverse Events by Dose Cohort
Grade ≥ 3 Adverse Events by Dose Cohort In biologically active dose cohorts, events were asymptomatic, transient and largely priming-related CTIM-76 Program Dose Level 22.5 µg 70 µg 140 µg 210 µg 280 µg 280 µg 560 µg Total Schedule QW QW QW QW QW Q3W QW Patients N=1 N=3 N=4 N=5 N=4 N=6 N=4 N=27 Even
Slide 16: Manageable Safety Profile, With CRS Limited to Grade 1–2
CTIM-76 Program CTIM-76 Demonstrates a Manageable Safety Profile, With CRS Limited to Grade 1–2 16 Context Therapeutics Inc. - November 2026 CTIM-76-related TEAEs in ≥ 10% of patients Cytokine release syndrome by dose level 3 (11.1%) 3 (11.1%) 3 (11.1%) 3 (11.1%) 4 (14.8%) 4 (14.8%) 4 (14.8%) 4 (14.
Slide 17: Promising Antitumor Activity in QW Biologically Active Dose Cohorts
Promising Antitumor Activity in QW Biologically Active Dose Cohorts Early efficacy signal in a heavily pretreated population supports advancing the QW biologically active doses Context Therapeutics Inc. - November 202617 Best Overall % Change in Tumor Size From Baseline* On treatment Other Endometri
Slide 18: Emerging Evidence of Durable Activity in QW Dose Cohorts
Emerging Evidence of Durable Activity in QW Biologically Active Dose Cohorts CTIM-76 Program 18 CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. RECIST-evaluable population (n=12 patients at target doses, QW) is defined as having measurable disease documented at b
Slide 19: Greater T-Cell Activation With Tumor Reduction
Greater T-Cell Activation With Tumor Reduction, Consistent With Target-Dependent Activity CTIM-76 Program Context Therapeutics Inc. - November 202619 Peak serum cytokines Activated CD8 T cells IFN-γ IL-2 CD69+ 10⁰ 10¹ 10² 10³ 10⁴ Reduction n=7 No Reduction n=11 *** Pe ak c on ce nt ra tio n, p g/ m
Slide 20: Duration of Treatment and Response in QW Dose Cohorts
CTIM-76 Program Duration of Treatment and Response in QW Biologically Active Dose Cohorts Context Therapeutics Inc. - November 202620 5.6 month median PFS (95% CI: 1.2-7.4 months) in late-line ovarian cancer CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. Swimmer
Slide 21: Treatment Duration With CTIM-76 vs Prior Therapy
Treatment Duration With CTIM-76 vs Prior Therapy Time on CTIM-76 exceeded the most recent prior regimen in the majority of patients CTIM-76 Program Context Therapeutics Inc. - November 202621 CTIM-76 (140–280 µg QW)Prior Treatment CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of Oc
Slide 22: Decrease in Tumor Size Across Diverse Metastatic Sites
CTIM-76 Program Decrease in Tumor Size Across Diverse Metastatic Sites, With Strong Responses in Liver Context Therapeutics Inc. - November 202622 Tumor size reduction by Location Target lesions with any decrease Liver Target Lesion Size Best % Change from Baseline Per Target Lesion CTIM-76-101 Clin
Slide 23: Cytokine Response Helps Inform Dose and Schedule Selection
Cytokine Response Helps Inform Dose and Schedule Selection CTIM-76 Program Context Therapeutics Inc. - November 202623 Peak serum cytokine by Dose Level IFN-γ IL-2 10⁰ 10¹ 10² 10³ 10⁴ DL1 22.5/22.5 µg n=1 DL2 22.5/70 µg n=2 DL3 70/140 µg n=3 DL3a 70/210 µg n=5 DL4 140/280 µg n=4 DL5 140/560 µg n=3 P
Slide 24: Cross-Trial Comparison of CTIM-76 and Other TCEs in PROC
CTIM-76 Program Cross-Trial Comparison of CTIM-76 and Other TCEs in PROC Context Therapeutics Inc. - November 202624 Encouraging tumor response, durability, and CRS rate Company Context Therapeutics Xencor Regeneron Immunocore Asset CTIM-76 XmAb541 Ubamatamab Brenetafusp Target CLDN6 CLDN6 MUC16 PRA
Slide 25: CT-202 Nectin-4 x CD3 bispecific antibody
CT-202 Nectin-4 x CD3 bispecific antibody Context Therapeut ics Inc . - November 202625
Slide 26: Nectin-4 Therapies Have the Potential to Reach a Large Patient Population
Nectin-4 Therapies Have the Potential to Reach a Large Patient Population >125,000 patients per year in the United States in Relapsed/Refractory (R/R) Setting CT-202 Program 26 Context Therapeutics Inc. - November 2026 Cancers Incidence (US Only) R/R Incidence Nectin-4 Positive Nectin-4 Med/High Pat
Slide 27: CT-202: Nectin-4 x CD3 T cell Engaging Bispecific Antibody
CT-202: Nectin-4 x CD3 T cell Engaging (TCE) Bispecific Antibody CT-202 Program Context Therapeutics Inc. - November 202627 α-Nectin-4 Fab α-CD3 scFv IgG1 backbone Silenced Fc Novel design incorporating logic gating to spare Nectin-4 in normal tissue • Because of its expression in healthy epidermal
Slide 28: Clinical Precedent De-Risks pH-Dependent Binding for CT-202
CT-202 Program Clinical Precedent De-Risks pH-Dependent Binding for CT-202 Context Therapeutics Inc. - November 202628 Gotistobart and Ultomiris provide the strongest precedent for CT-202's design Gotistobart BNT316 / ONC-392 — anti-CTLA-4 Ultomiris® ravulizumab-cwvz — anti-C5 Challenge addressed •
Slide 29: CT-202 Designed to Optimize Tumor Selectivity and Minimize Off-tumor Toxicity
CT-202 is Designed to Optimize Tumor Selectivity and Minimize Off-tumor Toxicity CT-202 Program Context Therapeutics Inc. - November 202629 AACR 2026, “Targeting solid tumors with pH-dependent dual-specific TCEs: First-in Human development of CT-202” Minimize Activity in Normal Tissues at pH7.4 T ce
Slide 30: CT-202 is Highly Active and Well Tolerated Across In Vivo Models
CT-202 is Highly Active and Well Tolerated Across In Vivo Models CT-202 Program Context Therapeutics Inc. - November 202630 Complete Tumor Regressions CT-202 demonstrated similar efficacy in BT474 breast cancer xenograft compared to an enfortumab TCE control antibody Lower Cytokine Induction CT-202
Slide 31: CT-202 Phase 1 Study Design
CT-202 Phase 1 Study Design An open-label, multi-center, dose escalation / expansion, safety, and PK study 31 CT-202 Program Context Therapeutics Inc. - November 2026 Screening Phase 1a Dose Escalation (Q2W Dosing) Key Inclusion Criteria • Patients with advanced metastatic urothelial, colorectal, an
Slide 32: Selected Nectin-4-directed Immune-engaging Programs
Selected Nectin-4-directed Immune-engaging Programs Programs differ in molecular format, immune effector, and conditional-activation strategy CT-202 Program Context Therapeutics Inc. - November 202632 Company Context Therapeutics Bicycle Therapeutics Rondo Therapeutics Marengo Therapeutics LabGenius
Slide 33: Corporate
Corporate 33 Context Therapeut ics Inc . - November 2026
Slide 34: Experienced Management Team
Corporate Experienced management team Clinical team has developed T cell therapies Our management team is supported by a Board with deep oncology experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Karen Chagin, MD Chief Medical Officer Context Therapeutics
Slide 35: Corporate Investment Highlights
Corporate Investment Highlights (Nasdaq: CNTX) Context Therapeutics Inc. - November 202635 Investment Rationale Anticipated Milestones Large Unmet Need Solid tumors and ADC resistance High-Value Targets Claudin 6 and Nectin-4 Strong Team Deep oncology experience Focus on clinical execution Q2 2027 C
Slide 36: Advancing T Cell Engagers for Solid Tumors
c o n t ex t © CONTEXT THERAPEUTICS 2026 context t h e r a p e u t i c s Advancing T Cell Engagers for Solid Tumors Co text Therapeut ics Inc . - November 202636
Slide 37: Glossary
Glossary Appendix MTD Maximum tolerated dose N.D. Not disclosed ORR Objective response rate PFS Progression-free survival PK Pharmacokinetic PR Partial Response PROC Platinum-resistant ovarian cancer QW Every week Q3W Every three weeks scFv Single-chain variable fragment SD Stable Disease TCE T cell
Context Therapeutics — Investor Presentation (November 2026) on 6ix